Nathalie Auber
@Sofinnova Investments, Inc.
Latest period2024 - Q3ReportedManaged Assets$1.26BTotal holdings58
Assets growth rate-34.51%Assets growth rate (2-Q avg)-13.66%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Sofinnova Investments, Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 58 positions.
Assets under management
The assets under management (AUM) of Sofinnova Investments, Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.26B in assets, with a quarterly growth rate of -34.51% and a 2-quarter average growth rate of -13.66%. The portfolio is managed by Nathalie Auber, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
DYNDyne Therapeutics Inc
| 2.21% | $27.733M 772,070 shares@ $35.92 avg price | Decreased -52.5% |
COGTCogent Biosciences Inc
| 1.95% | $24.464M 2.265M shares@ $10.8 avg price | Decreased -18.31% |
SNDXSyndax Pharmaceuticals Inc
| 1.21% | $15.15M 786,999 shares@ $19.26 avg price | Decreased -63.45% |
EWEdwards Lifesciences Corp
| 1.07% | $13.389M 202,898 shares@ $65.99 avg price | Decreased -83.42% |
BSXBoston Scientific Corp
| 0.91% | $11.382M 135,819 shares@ $83.8 avg price | Decreased -20.61% |
PHVSPharvaris N V
| 0.89% | $11.118M 600,302 shares@ $18.52 avg price | Decreased -0.2% |
EWTXEdgewise Therapeutics Inc
| 0.82% | $10.269M 384,767 shares@ $26.69 avg price | Decreased -19.11% |
RVMDRevolution Medicines Inc
| 0.74% | $9.218M 203,271 shares@ $45.36 avg price | Decreased -55.33% |
TGTXTg Therapeutics Inc
| 0.67% | $8.389M 358,644 shares@ $23.39 avg price | Decreased -80.73% |
ESTAEstablishment Labs Hldgs Inc
| 0.63% | $7.852M 181,476 shares@ $43.28 avg price | Decreased -57.72% |